Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Famotidine (H2-Receptor Antagonist)
Treatment for Peptic ulcer disease
Typical Dosage: 20-40mg once or twice daily
Effectiveness
70%
Safety Score
80%
Clinical Trials
4
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
20-40mg once or twice daily
Time to Effect
1-2 weeks for symptom relief, 6-8 weeks for healing
Treatment Duration
6-8 weeks for acute, often longer for maintenance
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$100
Side Effect Mgmt:$10
Total Annual:$140
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$200
Cost per Remission
$233.33
Famotidine (H2-Receptor Antagonist) Outcomes
for Peptic ulcer disease
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+70%
Remission Rate
+60%
Common Side Effects
Headache
+3%
Dizziness
+1%
Nausea
+1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
4 completed trials for Famotidine (H2-Receptor Antagonist) in Peptic ulcer disease
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
NCT02418312COMPLETEDNA
228 participants
INTERVENTIONAL
Kaohsiung City, Taiwan
Started: Jan 1, 2012
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
NCT02551744COMPLETEDNA
101 participants
INTERVENTIONAL
Kaohsiung City, Taiwan
Started: Jul 1, 2012
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
NCT00229424COMPLETEDPHASE3
325 participants
INTERVENTIONAL
1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan
Started: Apr 1, 2005
Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT03667703COMPLETEDPHASE4
70 participants
INTERVENTIONAL
Boston, United States
Started: Mar 10, 2019